Health-related quality of life (HRQoL) in relapsed/refractory (R/R) indolent NHL in the phase 3 augment trial of rituximab (R) plus lenalidomide (R2) versus r plus placebo

This article has no abstract
Epistemonikos ID: 5e79b817b78b9e5129ca6f438a4a7f07b9b49e92
First added on: Feb 11, 2025